Stocks:
5,167
ETFs:
2,288
Exchanges:
11
Market Cap:
$62.23T
24h Vol:
$10.06B
Dominance:
MSFT:4.87%
Stocklytics Platform
Instrument logo  BMRN
BioMarin Pharmaceutical
BMRN
73 / 100
High Growth
$88.63arrow_drop_down1.59%-$1.44

Performance History

Stocklytics logo
Key Stats
Open$89.67
Prev. Close$90.07
EPS0.87
DividendNon-Dividend
Next Earnings Date-
Dividend Yield %-
Market Cap$16.79B
PE Ratio101.87
LOWHIGH
Day Range88.29
90.18
52 Week Range76.02
99.56
Ratios
P/B Ratio3.54
Revenue$2.41B
Operating M. %4.37%
Earnings$167.64M
Earnings Growth %18.43%
EBITDA Margin %11.43%
ROE %3.51%
EPS0.87

Score Breakdown

Welcome to Stocklytics

Don't miss out on the opportunity to stay ahead in the ever-changing world of finance.

73vs 54. Market Avg.

All Score 73 / 100 is to help users identify stocks that trade at a low value relative to their fundamentals. Suitable for value investors such as Warren Buffet.

BMRNMARKET
Value4040
Quality6940
Ownership017
Growth7446
Dividends-37
warning

BioMarin Pharmaceutical 's Price growth average in the last 3 years of 4.37% is modest compared to market average of 5.94%. This indicates BMRN could be a bad value stock.

Financial Forecast

AI Price Prediction

line chart placeholder

Analyst Ratings

info
Analyst ratings for this stock instrument are based on analysts' assumptions and should not be solely relied upon for financial decisions.

Correlated Companies

PRICE$726.31
24H (%)arrow_drop_down2.63%
24H ($)-$19.64
MARKET CAP$690.55B
PRICE$501.13
24H (%)arrow_drop_up1.61%
24H ($)$7.95
MARKET CAP$432.28B
PRICE$147.91
24H (%)arrow_drop_up1.48%
24H ($)$2.17
MARKET CAP$356.43B
PRICE$125.78
24H (%)arrow_drop_up0.43%
24H ($)$0.55
MARKET CAP$318.60B

About BioMarin Pharmaceutical (BMRN)

BioMarin Pharmaceutical Inc. develops and commercializes therapies for people with serious and life-threatening rare diseases and medical conditions. Its commercial products include Vimizim, an enzyme replacement therapy for the treatment of mucopolysaccharidosis (MPS) IV type A, a lysosomal storage disorder; Naglazyme, a recombinant form of N-acetylgalactosamine 4-sulfatase for patients with MPS VI; and Kuvan, a proprietary synthetic oral form of 6R-BH4 that is used to treat patients with phenylketonuria (PKU), an inherited metabolic disease. The company's commercial products also comprise Palynziq, a PEGylated recombinant phenylalanine ammonia lyase enzyme, which is delivered through subcutaneous injection to reduce blood Phe concentrations; Brineura, a recombinant human tripeptidyl peptidase 1 for the treatment of patients with ceroid lipofuscinosis type 2, a form of Batten disease; Voxzogo, a once daily injection analog of c-type natriuretic peptide for the treatment of achondroplasia; and Aldurazyme, a purified protein designed to be identical to a naturally occurring form of the human enzyme alpha-L-iduronidase. In addition, it develops Roctavian, an adeno associated virus vector, for the treatment of patients with severe hemophilia A; BMN 331, an AAV5 mediated gene therapy, which is in Phase 1/2 clinical trial for people living with Hereditary Angioedema (HAE); and BMN 255 that is in Phase 1/2 clinical trial for treating primary hyperoxaluria. The company serves specialty pharmacies, hospitals, and non-U.S. government agencies, as well as distributors and pharmaceutical wholesalers in the United States, Europe, Latin America, and internationally. BioMarin Pharmaceutical Inc. has license and collaboration agreements with Sarepta Therapeutics, Ares Trading S.A., Catalyst Pharmaceutical Partners, Inc., and Asubio Pharma Co., Ltd. The company was incorporated in 1996 and is headquartered in San Rafael, California.

Sector
Healthcare
Industry
Biotechnology
CEO
Mr. Jean-Jacques Bienaime M.B.A., MBA
Headquarters
San Rafael
Employees
3082
Exchange
NASDAQ
add BioMarin Pharmaceutical  to watchlist

Keep an eye on BioMarin Pharmaceutical

Adding the right stocks to your watchlist can provide valuable insights and opportunities for strategic decision-making.

Frequently Asked Questions

search
help
What is BioMarin Pharmaceutical 's (BMRN) price per share?

The current price per share for BioMarin Pharmaceutical (BMRN) is $88.63. The stock has seen a price change of -$1.44 recently, indicating a -1.6% change. This reflects the stock's recent market performance and investor sentiment.

help
What is the 52-week high and low for BioMarin Pharmaceutical (BMRN)?

For BioMarin Pharmaceutical (BMRN), the 52-week high is $99.56, which is 12.33% from the current price. The 52-week low is $76.02, the current price is 16.59% above the 52-week low. This gives investors an insight into the stock's volatility and price range over the past year.

help
Is BioMarin Pharmaceutical (BMRN) a growth stock?

BioMarin Pharmaceutical (BMRN) has shown an average price growth of 4.37% over the past three years. It has received a score of 63 out of 100 based on the Stocklytics formula. The interpretation of this score in terms of classifying BioMarin Pharmaceutical as a growth stock may vary, considering it is one of many factors investors might evaluate, including market trends, financial performance, and future prospects of the company.

help
What is BioMarin Pharmaceutical (BMRN) stock price performance year to date (YTD)?

As of the latest data, BioMarin Pharmaceutical (BMRN) has a year-to-date price change of -9.63%. Over the past month, the stock has experienced a price change of 4.57%. Over the last three months, the change has been -5.75%. Over the past six months, the figure is 7.95%. Looking at a longer horizon, the five-year price change stands at 5.88%.

help
Is BioMarin Pharmaceutical (BMRN) a profitable company?

BioMarin Pharmaceutical (BMRN) has a net income of $167.64M, which represents the company's total earnings after all expenses have been deducted from revenues. The gross margin of 76.15% indicates the percentage of revenue that exceeds the cost of goods sold, and the operating margin of 4.37% reflects the percentage of revenue remaining after covering variable production costs, highlighting the efficiency of the company's core operations. Total revenue stands at $2.42B, with a revenue growth rate of 15.42%, providing insight into the company's sales performance and growth. The gross profit is $1.84B. Operating income is noted at $157.6M. Furthermore, the EBITDA is $309.69M.

help
What is the market capitalization of BioMarin Pharmaceutical (BMRN)?

BioMarin Pharmaceutical (BMRN) has a market capitalization of $16.8B. The average daily trading volume is 1.66M, indicating the stock's liquidity and investor engagement.

News

email

Sign up for our newsletter

Join our exclusive community of over one million investment enthusiasts and receive our free newsletter filled with analysis, news, and updates every weekday.

Approach investments with caution like a driver who slows down on a curvy road.